Therefore, the combination of sh-circQSOX1 and anti-CTLA-4 therapy is expected to provide a new direction for treating Treg cell-mediated immunotherapy resistance in colorectal cancer (156). The gene discussed is CTLA4; the disease is colorectal cancer.